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Background: Although the diagnostic process in celiac disease
(CeD) has been addressed in several international guidelines, little
is known about the actual proceeding in current clinical practice.
This study investigated the initial presentation, the diagnostic
process, follow-up evaluations, and adherence to a gluten-free diet
in CeD patients in a real-life setting in Switzerland from a patient’s
perspective.
Methods: We performed a large patient survey among unselected
CeD patients in Switzerland.
Results: A total of 1689 patients were analyzed. The vast majority
complained of both gastrointestinal and nonspeciﬁc symptoms
(71.5%), whereas 1.8% reported an asymptomatic disease course.
A total of 35.8% CeD patients were diagnosed by a non-
gastroenterologist. The diagnostic process diﬀered between non-
gastroenterologists and gastroenterologists, with the latter more
often using duodenal biopsy alone or in combination with serology
(94.7% vs. 63.0%) and nongastroenterologists more frequently
establishing the diagnosis without endoscopy (37.0% vs. 5.3%,
P<0.001). Follow-up serology after 6 months was performed only
in half of all patients (49.4%), whereas 69.9% had at least 1 follow-
up serology within the ﬁrst year after diet initiation. About 39.7%
had a follow-up endoscopy with duodenal biopsies (after a median
of 12mo; range, 1 to 600mo). The likelihood of receiving any
follow-up examination was higher in patients initially diagnosed by
a gastroenterologist.
Conclusions: A signiﬁcant proportion of CeD patients are diag-
nosed by nongastroenterologists. Under the diagnostic lead of the
latter, more than a third of the patients receive their diagnosis on
the basis of a positive serology and/or genetics only, in evident
violation of current diagnostic guidelines, which may lead to an
overdiagnosis of this entity.
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Celiac disease (CeD) is a systemic immune-mediateddisorder triggered by gluten intake in genetically pre-
disposed patients.1 CeD aﬀects 0.6% to 1.0% of the general
population worldwide,2–7 with a higher prevalence among
patients with other autoimmune disorders including type 1
diabetes mellitus or thyroid diseases and genetic disorders
such as Turner or Down syndrome.8 Regional diﬀerences
among comparably developed countries and a female pre-
ponderance for CeD have been described; however, the
reasons for these remain unclear.9,10 Increasing prevalence
in developing countries seems to be attributable to a west-
ern diet, changes in wheat production, better diagnostics,
and increased awareness of the disease.1 Serologic screening
studies suggest a high number of clinically unrecognized
CeD cases;2,9 accordingly, in most patients, CeD remains
undiagnosed.
CeD remains a diagnostic challenge due to the broad
range of possible clinical manifestations. In contrast, CeD
symptoms diﬀer according to age at manifestation: infants
more often suﬀer from diarrhea and failure to thrive,11
whereas adolescents may complain of extraintestinal man-
ifestations such as a short stature or neurological symp-
toms.12 However, typical gastrointestinal symptoms,
among which diarrhea is the most frequently reported, are
encountered in only half of all cases.13 Furthermore, some
CeD cases are suspected by laboratory ﬁndings only such as
elevated liver enzymes or otherwise unexplained iron-
deﬁciency anemia. Moreover, CeD may be incidentally
diagnosed during upper endoscopies performed for other
indications.
Current guidelines recommend serology and duodenal
biopsy for CeD diagnosis with biopsy considered as its
mainstay.14 Patients with a high clinical suspicion of CeD
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should undergo endoscopy and duodenal biopsy regardless
of the initial serologic testing. As an exception, recently
published European pediatric guidelines suggest a place for
CeD diagnosis without the need for duodenal biopsies in
the presence of typical symptoms, high serologic titers, and
predisposing human leukocyte antigen (HLA) genotypes
(DQ2 and/or DQ8).15 However, this practice remains
highly controversial outside Europe16 and among some
European pediatric gastroenterologists.17 It seems evident
that CeD diagnosis has to be established with high accuracy
in every patient considering its pronounced consequences
for patients’ everyday life: a gluten-free diet (GFD) with
life-long elimination of wheat, rye, and barley imposes
strong dietary restrictions and has social and economic
consequences. In addition, incorrectly diagnosed CeD
patients triggers signiﬁcant health care costs due to
unnecessary follow-up visits. Because of the need of a very
high diagnostic threshold, clinical improvement after
implementation of GFD is not considered suﬃcient to
secure the diagnosis of CeD.18 Furthermore, given that
histologic ﬁndings in CeD are characteristic, but non-
speciﬁc,19 some experts even recommend the repetition of
duodenal biopsies after 1 year of dietary therapy.14 How-
ever, how these sometimes conﬂicting expert recom-
mendations regarding CeD diagnosis are implemented in
clinical practice remains unclear. Close follow-up especially
in the ﬁrst year after diagnosis is recommended for all CeD
patients. Assessing adherence to GFD is key and consists of
4 steps: (i) clinical assessment of symptoms, (ii) a dietetic
review, (iii) serum antibodies, and (iv) possibly follow-up
biopsies, which are recommended if the condition does not
respond to GFD or if patients are at an increased risk of
lymphoma.14 Considering the evidence that adherence to
GFD and mucosal healing can prevent CeD complications,
such a thorough follow-up of CeD patients seems essen-
tial.20 However, compliance with these recommendations in
a real-life setting has not been addressed.
This study investigates the initial presentation, the
diagnostic process, follow-up evaluations, and adherence to
GFD in CeD patients in a real-life setting in Switzerland
from a patient’s perspective.
MATERIAL AND METHODS
Study Design
This large patient survey collected information about
CeD presentation, the diagnostic process, treatment, and
adherence to GFD on the basis of an exclusive patient
perspective. The call to CeD patients was made through
announcements in print news of the Celiac Community
Foundation of the German-speaking part of Switzerland
and on its website. Patients or their caregivers (for pediatric
patients) were prompted to report their own case to the
database using a standardized questionnaire. Patient
answers and all additional data were anonymized. The
study was presented to the local Ethics committee and the
need for approval was waived due to anonymized data
collection.
Patients and Data Collection
All patients diagnosed with CeD were eligible for
inclusion in this study. Data were exclusively collected
using a questionnaire, which included sections about: (1)
patient demographic data, (2) disease characteristics (ﬁrst
symptoms, age at disease onset) and diagnostic process, (3)
GFD and adherence to therapy, (4) disease course and
follow-up visits after implementation of dietary restrictions.
Clinical remission at follow-up visits was deﬁned as the
complete absence of any CeD symptom. For comparison
between adult and pediatric study populations, adults were
deﬁned as patients above the age of 18 years according to
other CeD studies.21
Statistical Analysis
For all statistical analyses, IBM software SPSS version
23.0.0 (2014 SPSS Science Inc., Chicago, IL) was used.
Categorical data are summarized as the percentage of the
group total. Comparisons between categorical data were
performed using the w2 test or the Fisher exact test in case
of a small sample size (n<10). A 2-sided P-value of <0.05
was regarded as statistically signiﬁcant. For a more detailed
subgroup analysis, patients who were younger than 18 years
at CeD diagnosis were excluded.
RESULTS
Patient Demographics
From a total of 3800 printed questionnaires, 1689
(44.4%) were returned and ﬁnally analyzed. Demographic
data of the study population have been published else-
where: 1284 participants were female (76%), the mean age
was 41.3 years (range, 0 to 92 y) with a mean age at CeD
diagnosis of 31.1 years (range, 0 to 83 y),22 and 449 patients
(26.6%) were below 18 years at the time of CeD diagnosis.
First Presentation and Diagnosis of CeD
Only 15.3% of the patients reported isolated gastro-
intestinal symptoms as their initial presenting symptoms.
The vast majority complained of both gastrointestinal and
nonspeciﬁc symptoms (71.5%). About 1.8% reported an
asymptomatic disease course. Among all symptoms, ﬂat-
ulence, abdominal pain, and diarrhea were the most fre-
quently reported with at least one of them was present in
>50% of all patients (Supplementary table 1, Supple-
mental Digital Content 1, http://links.lww.com/JCG/
A282).
Most patients ﬁrst presented to a non-
gastroenterologist (75.1%). However, the ﬁnal diagnosis of
CeD was established in only 35.8% of the cases by a non-
gastroenterologist (Table 1). Diagnostic delay by physicians
tended to be shorter if patients presented to a gastro-
enterologist ﬁrst (mean 31.6 vs. 41.3months, median 1.0 vs.
5.0months, P=0.093). About 16.4% of all patients were
diagnosed on the basis of serology and/or genetics (HLAII
DQ2 and DQ8), whereas in the vast majority of the cases,
the diagnosis was established by a combination of serology
and duodenal biopsy (46.9%) or biopsy alone (31.9%). In
the remaining cases, diagnostic steps were not speciﬁed.
Under the diagnostic lead of nongastroenterologists, the
diagnostic process diﬀered signiﬁcantly compared with that
of gastroenterologists: Gastroenterologists more often used
duodenal biopsy alone or in combination with serology
(94.7% vs. 63.0%, P<0.001), whereas diagnosis was more
frequently established without endoscopy by non-
gastroenterologists (37.0% vs. 5.3%, P<0.001). Diﬀer-
ences remained signiﬁcant if only adult patients (18 y or
above at diagnosis) were analyzed (95.6% vs. 58.5%, and
41.5% vs. 4.4%, P<0.001).
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CeD Treatment and Follow-Up
GFD remains the mainstay of therapy as 97.7% of the
patients reported having been treated by GFD. More than
3 of 4 patients (79.8%) received expert nutrition counseling.
This counseling was more often prescribed if CeD diagnosis
was established by a gastroenterologist (83.5% vs. 76.0%,
P=0.001). About 77.0% of all patients reported adhering
always and 20.7% with only minor mistakes to a GFD.
Patients who were only incidentally diagnosed with CeD
tended to adhere to dietary treatment less than patients
with symptoms at diagnosis (63.3% vs. 77.7%, P=0.06).
No diﬀerence regarding adherence to GFD was seen in
patients with gastrointestinal symptoms compared with
those with a nongastrointestinal presentation. Interestingly,
younger patients (aged below 30 y) reported higher adher-
ence than patients aged over 30 years (80.5% vs. 76.2% for
adherence “always” to GFD, P=0.05).
Follow-up serology after 6 months was performed in
half of all patients (49.4%), whereas 69.9% had at least 1
follow-up serology within the ﬁrst year after diet initiation.
Serology results were infrequently reported; however, at
least 19.3% had a positive serology after 6 months (53.8%
missing) and 18.5% after 12 months (41.9% missing),
respectively. About 39.7% of the patients had a follow-up
endoscopy with duodenal biopsies (median duration after
diet initiation 12mo; range, 1 to 600mo). In adult patients
(18 y or above). follow-up serologies were more frequently
performed if the CeD diagnosis was established by a gas-
troenterologist (at 6mo 58.7% vs. 51.2%, P=0.032, at
12mo 62.6% vs. 51.6%, P=0.002). In addition, follow-up
biopsies were more often performed in adult patients
diagnosed by a gastroenterologist compared with those
who were initially diagnosed by a nongastroenterologist
(54.0% vs. 44.9%, P=0.007) (for details, see Figure 1).
About 43.7% of the patients reported complete clinical
remission 6 months after GFD initiation. The proportion of
complete remission was 59.4% after 12 months compared
with 61.7% after 24 months. No diﬀerence regarding clin-
ical remission was seen in those patients initially diagnosed
by a gastroenterologist compared with those diagnosed by a
nongastroenterologist, either at 6 months or at 12 and 24
months after CeD diagnosis. Similar results were seen if
only adult patients were analyzed.
DISCUSSION
In this large patient survey, we report the presentation,
diagnostic work-up, treatment by GFD, and follow-up
evaluations in CeD from a patient’s perspective. In contrast
to actual CeD guidelines, up to one sixth of all CeD
patients were diagnosed by serology only: reaching even 4
of 10 patients if diagnosis was established by non-
gastroenterologists. Furthermore, we demonstrate a high
frequency of nonspeciﬁc, nonclassical CeD symptoms and a
mismatch between self-reported diet adherence and clinical
remission rates.
In accordance to Rampertab et al13 and other studies
evaluating the presentation of CeD,11 diarrhea and
abdominal pain are among the most frequently reported
CeD symptoms. However, >40% of our patients did not
suﬀer from diarrhea, which is believed to be the classical
CeD symptom. In addition, nonclassical gastrointestinal
TABLE 1. Diagnostic Work-up in Adult Patients (18 y or Above at Diagnosis) and in All Patients
Diagnostic Modality
Diagnosis by a Nongastroenterologist
(N=354) (100%) [n (%)]
Diagnosis by a Gastroenterologist
(N=758) (100%) [n (%)]
Adult patients (18 y or above at diagnosis)
Serology alone 126 (35.6) 26 (3.4)
EGD and biopsy alone 51 (14.4) 346 (45.6)
Serology and EGD/biopsy 156 (44.1) 379 (50.0)
Others (genetics alone, serology and genetics) 21 (5.9)
Genetics (3), genetics and serology (6),
not speciﬁed (12)
7 (0.9%)
Genetics (2), genetics and serology (2),
not speciﬁed (3)
P<0.001 (biopsy vs. nonbiopsy)
N=592 (100%) [n (%)] N=1006 (100%) [n (%)]
All patients
Serology alone 181 (30.6) 36 (3.6)
EGD and biopsy alone 105 (17.7) 430 (42.7)
Serology and EGD/biopsy 268 (45.3) 523 (52.0)
Others (genetics alone, serology and genetics) 38 (6.4)
Genetics (5), genetics and serology (14),
not speciﬁed (19)
17 (1.7)
Genetics (4), genetics and serology (8),
not speciﬁed (5)
P<0.001 (biopsy vs. nonbiopsy)
EGD indicates upper endoscopy.
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FIGURE 1. Follow-up evaluations in adult patients after diet
initiation.
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symptoms such as ﬂatulence, constipation, nausea, or
vomiting are frequently encountered. Only 15% presented
with isolated gastrointestinal symptoms, underlining the
crucial importance of awareness toward nonspeciﬁc CeD
presentations such as fatigue or unexplained weight loss.
Exceptional symptoms such as edema, skin lesions,
migraine, or even paresthesia are not uncommon in our
cohort; up to 1 of 10 patients presented with one of these
symptoms. In any case, in our cohort, most patients
recalled at least some presenting symptoms and an
asymptomatic disease course was reported only by 2%
patients. This number contrasts prior ﬁndings, for instance
by Rutz et al,23 suggesting a higher prevalence of asymp-
tomatic CeD compared with symptomatic forms. Given the
high frequency of nonspeciﬁc gastrointestinal and non-
gastrointestinal symptoms, CeD should also be considered
in the absence of a classical presentation with diarrhea and
abdominal pain. CeD screening in these patients will
possibly uncover more CeD cases as seen in the study of
Catassi et al.24
Importantly, we found that up to one sixth of all CeD
patients received their diagnosis without endoscopic
assessment on the basis of serology and/or genetics only.
This apparent clinical practice contrasts current CeD
diagnostic guidelines,14 which consider upper endoscopy
with duodenal biopsy as the mainstay in CeD diagnosis.
Furthermore, we demonstrate that CeD without endoscopy
was signiﬁcantly more often diagnosed by non-
gastroenterologists. Almost 4 of 10 nongastroenterologists
made a CeD diagnosis on the basis of serology and con-
comitant symptoms/signs only. If we further take into
account that up to one third of the patients received their
diagnosis by a nongastroenterologist, then in more than 200
patients (12%) CeD diagnosis was not established in
accordance to diagnostic guidelines. In addition to that,
even gastroenterologists did not follow diagnostic guide-
lines rigourously. In summary, >16% of all 1689 patients
did not receive their diagnosis correctly. Biagi et al25 have
recently shown that in 61 of 180 patients who did not
receive their CeD diagnosis correctly, the diagnosis of CeD
could not be conﬁrmed after reinvestigation. Thus, there
may indeed be a substantial risk of overdiagnoses of the
CeD entity and therefore unnecessary, lifelong dietary
restrictions and follow-up evaluations. This ﬁnding has
important clinical implications as implementing an accurate
diagnostic process14 might not only impact on individual
patient’s life but also safe health care costs.
The reported excellent adherence rate to GFD is
>70% in our cohort. Our results agree with previous
ﬁndings, although our adherence rates are deﬁnitely in the
upper limit. In addition, self-reported adherence rates are
notoriously higher than true adherence rates.26 In the meta-
analysis of Hall et al,27 strict adherence rates measured by
self-report ranged from 42% to 91%. In contrast to other
studies, where the eﬀect of age is unclear28,29 or younger age
even correlated with lower adherence,30,31 we found that
adult patients under 30 years of age show better adherence.
In addition, symptomatic CeD patients tend to adhere
better than those with an asymptomatic disease course, also
contrasting prior ﬁndings.27 In our cohort, high adherence
rates to GFD contrast with the relatively lower rates of
clinical remission of 50% at 6 months after diagnosis,
although some increase was observed over the following
2 years. This mismatch may certainly be explained
by a self-report assessment and therefore a possible
misinterpretation of adherence to GFD by each individual
patient, despite a relatively high proportion of patients
receiving specialized nutrition counseling. Of note, such
counseling was more often prescribed, if a gastro-
enterologist was involved in the CeD diagnosis and follow-
up evaluations. In addition, follow-up examinations
(serology, biopsy) were more often ordered/performed by
gastroenterologists. However, both gastroenterologists and
nongastroenterologists did not use them as recommended
in expert guidelines. It remains unclear whether the more
rigorous but imperfect follow-up by gastroenterologists
impacts the clinical course of patients because neither
adherence rates to GFD nor rates of clinical remission were
higher in patients diagnosed and treated by a gastro-
enterologist compared with a nongastroenterologist.
Our study has several limitations: (i) exclusively rely-
ing on self-reports may have led to an overestimation of
adherence rates. However, these rates are comparable to
those in other studies27 and verifying true adherence
remains a challenge regardless of assessment by a physician.
(ii) Because of the retrospective assessment of symptoms,
our results are prone to recall bias. (iii) Another limitation
may be the absence of external validation including physi-
cian assessment or chart review. Misperception of diag-
nostic steps may have led to an overestimation of CeD cases
diagnosed without endoscopy and duodenal biopsy. How-
ever, the rates of missing values regarding the CeD diag-
nostic process are low [78/1689 (4.6%) in all patients; 6/
1124 (3.2%) in adult patients], supporting an adequate
patient perception. (iv) Another limitation is a possible
selection bias due to exclusive inclusion of patients who
were members of the Celiac Community Foundation of the
German-speaking part of Switzerland. Patients with a
symptomatic CeD course may more likely be members of
this foundation, which is supported by the fact that
asymptomatic CeD patients are underrepresented in this
study.
In conclusion, more than 1 of 3 CeD patients are
diagnosed by nongastroenterologists. Under the diagnostic
lead of nongastroenterologists, more than a third of the
patients receive their diagnosis on the basis of a positive
serology and/or genetics only, in evident violation of cur-
rent diagnostic guidelines.14 This may lead to a substantial
proportion of overdiagnoses and therefore unnecessary,
potentially lifelong dietary restrictions as well as follow-up
evaluations in these patients. In addition, nonspeciﬁc non-
classical symptoms—either gastrointestinal or nongastro-
intestinal—are frequent, and lack of diarrhea and/or
abdominal pain should not delay diagnostic work-up.
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